Search
Girentuximab
go.drugbank.com/drugs/DB05304InvestigationalGirentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).
Perennial Allergic Rhinitis (PAR)
go.drugbank.com/conditions/DBCOND0058482Drugs: Azelastine · Beclomethasone dipropionate · Cetirizine · Ciclesonide · Cortisone acetate · Cromoglicic acid +12 moreSynonyms: Rhinitis allergic NOS, Allergic rhinitis NOSClocortolone
go.drugbank.com/drugs/DB00838ApprovedClocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Lubazodone
go.drugbank.com/drugs/DB09196ExperimentalLubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was
7MW3711
go.drugbank.com/drugs/DB19298InvestigationalDeveloped by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]
Ronacaleret
go.drugbank.com/drugs/DB05255InvestigationalRonacaleret is a calcium-sensing receptor antagonist.
Ergotamine
go.drugbank.com/drugs/DB00696ApprovedA vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Categories: Analgesics, Non-NarcoticCutaneous Melanoma
go.drugbank.com/conditions/DBCOND0040978Drugs: IpilimumabSynonyms: Melanoma, NOS, [M]Malignant melanoma NOS or melanocarcinoma or melanoma NOSMelanoma
go.drugbank.com/conditions/DBCOND0020306Synonyms: Melanoma, NOS, [M]Malignant melanoma NOS or melanocarcinoma or melanoma NOSIR208
go.drugbank.com/drugs/DB05106InvestigationalIR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.